
Sign up to save your podcasts
Or
Jonathan Violin, CEO of Crescent Biopharma and Venture Partner at Fairmount, speaks with Venrock partner Nimish Shah about how the company is keeping a frenetic and exciting pace to generate a new class of drugs while preparing to launch on the public markets later this year.
4.8
6262 ratings
Jonathan Violin, CEO of Crescent Biopharma and Venture Partner at Fairmount, speaks with Venrock partner Nimish Shah about how the company is keeping a frenetic and exciting pace to generate a new class of drugs while preparing to launch on the public markets later this year.
1,270 Listeners
2,184 Listeners
1,014 Listeners
987 Listeners
1,777 Listeners
2,293 Listeners
3,981 Listeners
123 Listeners
317 Listeners
5,915 Listeners
1,542 Listeners
31 Listeners
146 Listeners
10 Listeners
45 Listeners